Sun Pharmaceutical Industries shares gained after the US FDA has granted its subsidiary final approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Temodar, Temozolomide Capsules, 5 mg, 20 mg, 100 mg, 140 mg, 180 mg and 250 mg.

Temozolomide Capsules, 5 mg, 20 mg, 100 mg, 140 mg, 180 mg and 250 mg are therapeutic equivalents of Merck Sharp & Dohme Corporation's Temodar Capsules.

Shares of the company are trading at Rs 622.30, up Rs 7.6, or 1.24% at the Bombay Stock Exchange (BSE) on Friday at 10:07 a.m.

The scrip has touched an intra-day high of Rs 626.25 and low of Rs 619.10. The total volume of shares traded at the BSE is 71,518.

In the earlier session, the shares climbed 0.6%, or Rs 3.65, at Rs 614.70.

Currently, the stock is trading down 4.26% from its 52-week high of Rs 650.00 and above 61.57% over the 52-week low of Rs 385.15.